sampletargeted lipolysis
98%+ · 10mg · Lyophilized · MW: 1815.1
Bulk discount
3+ pcs
€47.40
−5%
5+ pcs
€44.91
−10%
10+ pcs
€42.41
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
AOD-9604
Advanced Obesity Drug | Modified hGH Fragment 176-191
In short
Modified growth hormone fragment studied in metabolic models for lipolytic activity without affecting blood glucose levels.
Best sellers
Related resources
Ready-to-use starter kit
AOD-9604 is a modified fragment of the human growth hormone (hGH) with an added tyrosine amino acid. At the molecular level, it interacts with beta-3 adrenergic receptors (β3-AR) to stimulate fat breakdown (lipolysis) and inhibit the formation of new fat cells, without the growth-promoting effects of the full hormone. Scientists investigate this peptide primarily in laboratory settings (in vitro) and animal models to analyze its influence on fat metabolism. This product is strictly for scientific research purposes and is not an approved medication.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
AOD-9604 is a modified fragment of human growth hormone (hGH amino acids 177-191) with an N-terminal tyrosine, developed by Professor Frank Ng at Monash University in collaboration with Metabolic Pharmaceuticals Ltd (Australia). It stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation without the growth-promoting effects of full hGH. Six clinical trials enrolling ~900 participants demonstrated excellent safety but the pivotal Phase IIb trial failed to show clinically meaningful weight loss, leading to development termination in 2007. Australia's TGA has approved it as iTRAM for intra-articular knee osteoarthritis. It is not FDA-approved and is WADA-prohibited.
HGH 177-191 fragment + tyrosine - lipolysis selective No diabetogenic activity of full HGH Chondrogenic stimulation for osteoarthritis research Standard fasted-morning dose 250-500 mcg s.c.
AOD-9604 acts through a dual mechanism: acutely, it stimulates lipolysis and energy expenditure through receptor-independent pathways; chronically, it upregulates beta-3 adrenergic receptor (β3-AR) expression in adipose tissue (restoring levels to lean-equivalent) to sustain fat oxidation. This was confirmed by knockout mouse studies where acute effects persisted but chronic weight loss was abolished without β3-AR. Crucially, it does not bind the GH receptor, does not increase IGF-1, and does not cause hyperglycemia or cell proliferation.
Primary research indication. Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
Reduces fat synthesis and storage in adipose tissue. Effects demonstrated in both animal models and isolated human adipose tissue.
Unlike full hGH, does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance. Safer metabolic profile.
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Morning on empty stomach, 30 min before food
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 5.0
5.0marks
Standard insulin syringe 1 ml (100 marks)
Concentration
5.00mg/ml
Dose volume
0.050ml
U-100 units
5.0units
Doses per vial
40doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (10 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Morning on empty stomach, 30 min before food
Allow vial to reach room temperature (15-20 minutes)
Calculate required BAC water volume using calculator below
Draw BAC water into syringe
Inject slowly down vial side (not directly onto powder)
Gently swirl until dissolved (never shake vigorously)
Store reconstituted solution at 2-8°C and use within 28 days
Excellent safety in 6 RCTs (~900 participants) — zero serious adverse events, profile indistinguishable from placebo
158,989 US compounding prescriptions filled with zero FAERS adverse event reports (as of 2024)
Does not affect blood glucose, insulin, or — safer metabolic profile than full
No anti-AOD-9604 antibodies detected in any trial participant
May cause mild injection site reactions
Not recommended during pregnancy or breastfeeding
WADA prohibited substance — banned at all times under S.0 category
Long-term safety beyond 24 weeks has not been studied
recommended against 503A bulks list inclusion in Dec 2024 citing immunogenicity concerns
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Human Safety & Tolerability — Pooled Analysis of 6 RCTs (2013)
~900 obese adults | Oral 0.25-54mg/day & IV 25-400µg/kg | 6 trials | Safety indistinguishable from placebo
Pooled analysis of all six randomized, double-blind, placebo-controlled clinical trials of AOD-9604. Zero serious adverse events attributed to AOD-9604, zero treatment-related discontinuations. No clinically significant changes in IGF-1, glucose, or insulin. No anti-AOD-9604 antibodies detected in any participant. Adverse events (headache, mild GI symptoms) were comparable to placebo.
View the studyPhase IIa — Oral AOD-9604 for Obesity (2001-2002)
300 obese adults | Oral 0.25, 0.5, 1.0mg/day | 12 weeks | Significant weight loss at 1mg
Randomized, double-blind, placebo-controlled trial in 300 obese adults. The 1mg/day oral group achieved 2.8kg mean weight loss vs 0.8kg for placebo (statistically significant). This positive result led to the larger Phase IIb OPTIONS trial.
View the studyPhase IIb OPTIONS Trial — Oral AOD-9604 for Obesity (2006)
536 obese adults | Oral dosing | 24 weeks | Failed primary endpoint
The pivotal Phase IIb multicenter trial. Despite full enrollment of 536 subjects, AOD-9604 showed no statistically significant weight loss vs placebo at 12 or 24 weeks. The trial incorporated intensive diet and exercise, which may have masked modest peptide effects. Development was terminated in March 2007 by Metabolic Pharmaceuticals.
View the studyOsteoarthritis Cartilage Repair Study (2015)
Rabbits (n=32) | 0.25mg weekly intra-articular | 4-7 weeks | Enhanced cartilage regeneration
Combined AOD-9604 and hyaluronic acid injections were more effective than either alone. Lameness recovery was fastest in the combination group (11±4 days vs 25±2 days for controls). AOD-9604 enhanced cartilage regeneration without stimulating IGF-1.
View the studyDetection and Metabolism Study (2015)
In vitro | Various concentrations | Metabolite identification
Validated detection method with 50 pg/mL limit. Identified six potential metabolites. The metabolite CRSVEGSCG proved significantly more stable than the parent compound in serum. Confirmed peptide sequence structure.
View the studyFat Oxidation and Weight Loss in Obese Mice (2001)
Mice | Mini-osmotic pumps | 14 days | Significant weight reduction and increased fat oxidation
Both hGH and AOD-9604 significantly reduced body weight gain in obese mice, correlated with increased in vivo fat oxidation and plasma glycerol levels. Importantly, AOD-9604 did not cause hyperglycemia or reduce insulin secretion like full hGH.
View the studyBeta-3 Adrenergic Receptor Mechanism Study (2001)
Mice & Beta-3-AR knockout mice | 14 days | Increased beta-3-AR expression, reduced adipose tissue
Treatment reduced body weight and adipose tissue while increasing beta-3-AR expression to levels comparable with lean mice. In knockout mice, chronic effects were abolished but acute energy expenditure increases persisted.
View the studyOral Administration Effects on Lipid Metabolism (2000)
Mice | Oral daily | 30 days | Reduced lipogenesis, increased lipolysis
From day 16 onward, body weight gain was significantly lower than controls. The compound significantly reduced lipogenic activity and increased lipolytic activity in adipose tissue. Effects also demonstrated on isolated human adipose tissue.
View the studyAntilipogenic Action of C-Terminal hGH Fragment (1993)
In vitro | Various concentrations | Demonstrated antilipogenic activity
Foundational study showing the synthetic C-terminal peptide fragment demonstrated antilipogenic activity identical to intact hGH. Established that the antilipogenic functional domain resides in the C-terminal region of growth hormone.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
